BRIEF-Intellia And Regeneron Announce Clinical Data For NTLA-2001
Reuters2021-06-26
June 26 (Reuters) - Regeneron Pharmaceuticals Inc :
* INTELLIA AND REGENERON ANNOUNCE LANDMARK CLINICAL DATA SHOWING DEEP REDUCTION IN DISEASE-CAUSING PROTEIN AFTER SINGLE INFUSION OF NTLA-2001, AN INVESTIGATIONAL CRISPR THERAPY FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS
* REGENERON PHARMACEUTICALS - INTERIM READOUT IN ONGOING PHASE 1 TRIAL FINDS SINGLE 0.3 MG/KG DOSE OF NTLA-2001 LED TO 87% MEAN REDUCTION IN SERUM TTR
* NO SERIOUS ADVERSE EVENTS OBSERVED IN FIRST SIX PATIENTS BY DAY 28
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
